Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status approved; investigational
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 62350-0077; 68682-272; 72189-084; 0168-0432; 22365-121; 51672-4174; 99207-271; 66039-829; 71052-160; 64552-4008; 45802-368; 51552-1538; 62147-0087; 51672-4145; 63629-8818; 68462-536; 51927-0168; 72643-006; 0093-3133; 99207-260; 99207-270; 99207-276; 58175-0397; 62147-0072
UNII P1QW714R7M
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Proteinuria20.02.01.011--
Pruritus23.03.12.0010.006014%
Psoriasis23.03.14.002; 10.02.01.0360.002151%Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.002--Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000878%Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Punctate keratitis06.04.02.0030.000658%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000439%
Pyrexia08.05.02.0030.005619%
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000966%Not Available
Rash papular23.03.13.0170.000658%Not Available
Rash pustular23.03.10.003; 11.01.12.002--
Red blood cell count decreased13.01.05.007--Not Available
Retinal vein occlusion24.01.07.006; 06.10.01.0100.000439%Not Available
Rhabdomyolysis15.05.05.0020.000439%
Rhinitis22.07.03.006; 11.01.13.004--
Scab23.03.03.0040.007331%Not Available
Scar23.03.11.008; 12.01.06.008--Not Available
Scrotal oedema21.12.02.001--Not Available
Scrotal pain21.12.02.004--
Scrotal ulcer21.12.02.007; 23.07.03.007--Not Available
Seborrhoeic keratosis23.10.01.008; 16.26.01.008--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin atrophy23.01.05.0010.000966%
Skin depigmentation23.05.02.0020.002897%Not Available
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene